Physician profile
Ryan M Jordan
NPI 1114362860
$4,276.15
in general payments reported to CMS, 2019-2025
26 companies · $976 in 2025
The $976 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $377 · 2021: $539 · 2022: $625 · 2023: $507 · 2024: $618 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,533.21 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.38 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $314.52 | 2019-2023 | |
| Pfizer INC. | $269.30 | 2019-2025 | |
| Boston Scientific Corporation | $194.03 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $143.28 | 2020-2024 | Linzess |
| Philips North America LLC | $140.90 | 2025 | Lm Undivided |
| Janssen Biotech, INC. | $138.46 | 2022-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $131.46 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $128.73 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $110.19 | 2019-2024 | Dificid |
| Aimmune Therapeutics, INC. | $98.71 | 2024-2025 | Zenpep |
| Abbott Laboratories | $95.19 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $83.96 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $70.00 | 2025 | Entyvio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $52.31 | 2025 | Ozempic, Wegovy |
| Celgene Corporation | $32.68 | 2021-2024 | Zeposia |
| Exact Sciences Corporation | $31.65 | 2024-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $31.14 | 2025 | |
| Braintree Laboratories, INC. | $27.32 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $25.48 | 2024 | Givlaari |
| Ferring Pharmaceuticals INC. | $20.80 | 2021 | |
| Intercept Pharmaceuticals, INC. | $18.69 | 2025 | |
| Vivus LLC | $18.57 | 2025 | Pancreaze |
| Allergan, INC. | $14.67 | 2020 | |
| Dynavax Technologies Corporation | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.